Free tool
FAERS Monitor: Erbitux
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125084 or its brand name (Erbitux, Cetuximab). Reports on generic versions are filed under their own applications.
Reports
31,703
Serious
27,066
85% of reports
Hospitalization
12,726
Death reported
4,267
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash2,287
- diarrhoea2,049
- off label use1,923
- nausea1,677
- vomiting1,415
- dyspnoea1,411
- neutropenia1,243
- pyrexia1,137
- malignant neoplasm progression1,136
- infusion related reaction1,113
- dehydration1,106
- fatigue1,096
- death1,084
- hypotension940
- anaemia935
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 691 |
| 2005 | 1,076 |
| 2006 | 1,313 |
| 2007 | 1,079 |
| 2008 | 1,212 |
| 2009 | 1,407 |
| 2010 | 1,576 |
| 2011 | 1,639 |
| 2012 | 1,656 |
| 2013 | 1,541 |
| 2014 | 1,570 |
| 2015 | 1,412 |
| 2016 | 1,537 |
| 2017 | 1,913 |
| 2018 | 1,472 |
| 2019 | 1,437 |
| 2020 | 1,152 |
| 2021 | 1,237 |
| 2022 | 1,283 |
| 2023 | 1,385 |
| 2024 | 1,371 |
| 2025 | 1,471 |
| 2026 | 1,273 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,022,456 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 1,113 | 11.3 | 10.7 | 10,310 |
| malignant neoplasm progressionSignal | 1,136 | 7.4 | 7.0 | 6,276 |
| neutropeniaSignal | 1,243 | 6.1 | 5.8 | 5,295 |
| dehydrationSignal | 1,106 | 5.5 | 5.2 | 4,101 |
| rashSignal | 2,287 | 3.5 | 3.4 | 4,133 |
| anaemiaSignal | 935 | 3.3 | 3.1 | 1,472 |
| hypotensionSignal | 940 | 3.1 | 2.9 | 1,358 |
| pyrexiaSignal | 1,137 | 2.2 | 2.1 | 738 |
| diarrhoeaSignal | 2,049 | 2.1 | 2.0 | 1,228 |
| vomiting | 1,415 | 2.0 | 1.9 | 720 |
| dyspnoea | 1,411 | 1.7 | 1.6 | 375 |
| off label use | 1,923 | 1.5 | 1.4 | 288 |
| nausea | 1,677 | 1.4 | 1.3 | 204 |
| fatigue | 1,096 | 0.9 | 0.9 | 5 |
| death | 1,084 | 0.8 | 0.8 | 37 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.